Ibrutinib elicited G1 cell cycle arrest and apoptosis in both MYC and HER2 amplified tumors, suggesting this drug could be used to treat biomarker-selected groups of patients with esophageal cancer. This evidence concerns the gene MYC and esophageal cancer.